Use

PrismRA is a blood‑based molecular signature response classifier (MSRC) designed to predict inadequate response to tumor necrosis factor inhibitor (TNFi) therapy in patients with rheumatoid arthritis (RA). It analyzes RNA transcripts and anti‑CCP antibody levels, combining molecular and clinical features, to guide therapy decisions and avoid ineffective TNFi treatment by identifying likely non‑responders prior to therapy initiation. Physicians receive a personalized score report to inform choice of alternative effective treatments.